Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Mayo Clinic
University of Illinois at Chicago
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
University of California, San Francisco
Novartis
Tufts Medical Center
National Institutes of Health Clinical Center (CC)